Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review

Area of Science:

• Cardiovascular Health
• Endocrinology
• Women's Health

Background:

• Unopposed postmenopausal estrogen therapy demonstrates cardioprotective effects, partly via beneficial impacts on lipid and lipoprotein metabolism.
• Limited data exist on coronary heart disease (CHD) risk reduction with combined estrogen-progesterone therapy.
• Continuous estrogen-progesterone therapy is explored for maintaining estrogen's cardiovascular benefits while preventing endometrial hyperplasia.

Purpose of the Study:

• To evaluate the role of estrogen-progesterone therapy in CHD risk reduction.
• To compare continuous versus cyclic estrogen-progesterone therapy regarding cardiovascular and endometrial outcomes.
• To inform clinical guidelines for hormone replacement therapy.

Main Methods:

• Review of existing data on postmenopausal hormone therapy.
• Analysis of lipid and lipoprotein metabolism in women undergoing hormone therapy.
• Assessment of endometrial cancer incidence in relation to therapy type.

Main Results:

• Estrogen therapy alone shows benefits for coronary heart disease (CHD).
• Continuous estrogen-progesterone therapy may preserve cardiovascular benefits and reduce endometrial cancer risk compared to estrogen alone.
• Further controlled clinical trials are needed.

Conclusions:

• Estrogen-progesterone therapy warrants further investigation for postmenopausal women's cardiovascular health.
• Continuous administration may offer a safer alternative to unopposed estrogen.
• Clinical guidelines for hormone replacement therapy require robust evidence from controlled trials.